Bellwether Interviews: Free Research Report for Express Scripts Inc.

Mar 14, 2008 (M2 PRESSWIRE via COMTEX) -- ESRX | news | PowerRating | PR Charts -- BellwetherReport.com is always trying to get the edge on the market and have introduced a new service that will consist of interviewing top independent research analysts along with CEO's and Management of some of the top companies on the US, Canadian and Foreign markets. Yesterday we had a conversation with Brian Sozzi of Wall Street Strategies, to ask his professional opinion on Express Scripts Inc. (NASDAQ:ESRX). We have included our a summary of the conversation below, but do suggest that investors looking to receive research on ESRX sign up for free to BellwetherReport.com for more information as it becomes available. Also members looking to receive a free custom stock review on any company they currently hold in their portfolio are welcome to sign up and submit their query in the members section of www.bellwetherreport.com under the tab "request a stock review".

This conversation was conducted on March 12th 2008.

Q: What's your take on Express Scripts Inc.?

A: Shares of Express Scripts have come under considerable selling pressure amid worrisome news from managed healthcare companies Wellpoint (WLP) and Humana (HUM). These industry heavyweights have issued somewhat disappointing 2008 financial guidance, blaming the shortfall versus consensus on slower enrollee growth and rising medical costs. Toss in the strong advance of stocks such as Express Scripts (ESRX), Medco Health Solutions (MHS), and McKesson (MCK) over the past 52-weeks and the profit taking by investors really isn't much of a surprise.

Q: So, what is your position on all this?

A: Nonetheless, we continue to be quite positive on the pharmaceutical benefit management industry as these drug middlemen will capitalize on favorable industry dynamics associated with generic and brand drugs. Specifically to Express Scripts, it's increasingly shifting clients to lower cost generic drug alternatives, which is creating an upward trend in the critical gross profit and EBITDA per adjusted claim metrics.

Q: Based on this, what would you tell investors looking to position themselves in this stock?

A: We suspect the company's ability to lower its drug purchasing costs and offer value to clients will lead to strong double-digit percentage earnings growth in 2008.

For a free custom Stock Review on ESRX or for any other security in your portfolio sign up to www.bellwetherreport.com and in the members' area click "custom stock review".

The Bellwether Report will continue scanning the markets for true emerging growth opportunities that will show subscribers optimal entry points with profitable exit points. If you are interested in receiving more information on feel free to sign up for a 3 month complimentary subscription to the #1 online investment resource www.bellwetherreport.com.

All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Delivery, and or timely delivery of Internet mail is not guaranteed. Wall Street Strategies therefore recommends that you do not rely on email as your sole method of communication with us. Wall Street Strategies recommends using a POP3 or IMAP email account with an email client such as Microsoft Outlook or Eudora. Free web-based email accounts are not advised as they are subject to quotas, filters and frequent delays.Disclaimer: All investment entails inherent risk. Wall Street Strategies' research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. Wall Street Strategies, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. Wall Street Strategies, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of Wall Street Strategies sit on the Board of Directors of any covered company. Wall Street Strategies is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness. The statements made herein contain general information and do not constitute an offer to buy or sell any security.

Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.

Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index